lubazodone hydrochloride has been researched along with citalopram in 4 studies
| Studies (lubazodone hydrochloride) | Trials (lubazodone hydrochloride) | Recent Studies (post-2010) (lubazodone hydrochloride) | Studies (citalopram) | Trials (citalopram) | Recent Studies (post-2010) (citalopram) |
|---|---|---|---|---|---|
| 12 | 0 | 1 | 5,348 | 1,424 | 2,350 |
| Protein | Taxonomy | lubazodone hydrochloride (IC50) | citalopram (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.297 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.196 | |
| Aromatase | Rattus norvegicus (Norway rat) | 0.0018 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.196 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 3.289 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.297 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0227 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.0027 | |
| Histamine H1 receptor | Homo sapiens (human) | 3.194 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.839 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.1869 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.398 | |
| Transporter | Rattus norvegicus (Norway rat) | 8.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, M; Hatanaka, K; Hattori, H; Koshiya, K; Nakato, K; Sonoda, R; Takeuchi, H; Yamaguchi, T; Yatsugi, S | 1 |
| Hatanaka, K; Yamaguchi, T; Yatsugi, S | 2 |
| Takeuchi, H; Yamaguchi, T; Yatsugi, S | 1 |
4 other study(ies) available for lubazodone hydrochloride and citalopram
| Article | Year |
|---|---|
Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity.
Topics: Animals; Citalopram; Fluoxetine; Learning; Mice; Mice, Inbred ICR; Morpholines; Olfactory Bulb; Oxotremorine; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Tremor | 1997 |
Effect of acute treatment with YM992 on extracellular serotonin levels in the rat frontal cortex.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Cerebral Cortex; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Extracellular Space; Fluorobenzenes; Fluoxetine; Frontal Lobe; Male; Morpholines; p-Chloroamphetamine; Piperidines; Rats; Rats, Wistar; Serotonin; Serotonin Agents; Serotonin Antagonists; Synaptosomes; Tritium; Venlafaxine Hydrochloride | 2000 |
Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Extracellular Space; Fluorobenzenes; Fluoxetine; Frontal Lobe; Male; Morpholines; Norepinephrine; Piperidines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Venlafaxine Hydrochloride | 2000 |
Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Injections, Intraperitoneal; Male; Mice; Mice, Inbred ICR; Morpholines; Motor Activity; Obsessive-Compulsive Disorder; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors | 2002 |